Audio Journal of Oncology in Advance – March 1st, 2008

Volume 16 Number 5 (March 1st, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
Gastrointestinal Cancers Symposium (January 25-27, 2008, Orlando)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)

Richard Stone

George Canellos

Dasatinib: Durable Responses in Chronic Myeloid Leukemia

Richard Stone, Dana-Farber Cancer Institute, BostonCOMMENT:George Canellos, Dana-Farber Cancer Institute, Boston
Data released at the ASH conference show that dasatinib has given durable responses in patients with chronic phase chronic myeloid leukemia for whom imatinib has failed, or who cannot tolerate imatinib. In AtlantaRichard Stonediscussed his findings with Derek Thorne, who then askedGeorge Canellosto reflect on them.

Anton Hagenbeek

George Canellos

Ibritumomab Benefits Patients With Follicular Lymphoma

Anton Hagenbeek, University of UtrechtCOMMENT:George Canellos, Dana-Farber Cancer Institute, Boston
In patients with advanced-stage follicular non-Hodgkin’s lymphoma the radiolabeled antibody ibritumomab tiuxetan prolonged progression-free survival, according to a study reported at the ASH meeting. Sarah Maxwell spoke to the authorAnton Hagenbeek.George Canellosput the data into context.

Charles Hsu

Robert Mayer

Adjuvant Chemoradiotherapy: Sizable Gains In the Treatment of Pancreas Cancer

Charles Hsu, Johns Hopkins University, BaltimoreCOMMENT:Robert Mayer, Dana-Farber Cancer Institute
Patients with resectable pancreas cancer lived longer when treated with adjuvant radiation plus chemotherapy, according to a study reported at the gastrointestinal cancers conference in Orlando.Charles Hsutalked with Peter Goodwin about their findings;Robert Mayerassessed the work.

Pierre Fenaux

Azacitidine New Standard In High Risk Myelodysplastic Syndromes

Pierre Fenaux, Hôpital Avicenne, Paris
Phase III study results presented at ASH found the hypomethylating agent azacitidine was best for patients with high-risk MDS.Pierre Fenauxgave the details to Derek Thorne, who also heard fromGeorge Canellos.

Bart Barlogie

Total Therapy Possible Cure For Multiple Myeloma?

Bart Barlogie, University of Arkansas, Little Rock
The total therapy clinical studies of multiple myeloma reported promising findings to the Hematologic Malignancies Congress in Paris.Bart Barlogietalked with Peter Goodwin about the new data from melphalan-induced tandem autologous transplants with additional thalidomide or bortezomib therapy.

LISTEN

To subscribe to the ASCO Audio Journal of Oncology podcast please go toASCO Audio Journal of Oncology in Advance Presentationsorclick here.